Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer

British Journal of Cancer

Volumn 89, Issue 6, 2003, Pages 1028-1030

  Forrest, L M ^a   McMillan, D C ^a   McArdle, C S ^a   Angerson, W J ^a   Dunlop, D J ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Albumin; C reactive protein; Cumulative prognostic score; Non small cell lung cancer; Performance status; Stage

Indexed keywords

C REACTIVE PROTEIN; CISPLATIN;

ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HYPOALBUMINEMIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MOLECULAR RECOGNITION; PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; STANDARDIZATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADENOCARCINOMA; ALBUMINS; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; HYPOALBUMINEMIA; INFLAMMATION; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 0141887346     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601242     Document Type: Article

References (16)

1. Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y, Sakai S (2001) Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 85: 1634-1639
2. Arias-Diaz J, Vara E, Torres-Melero J, Garcia C, Baki W, Ramirez-Armengol JA, Balibrea JL (1994) Nitrite/nitrate and cytokine levels in bronchoalveolar lavage fluid of lung cancer patients. Cancer 74: 1546-1551
3. Herndon II JE, Fleishman S, Kornblith AB, Kosty M, Green MR, Holland J (1999) Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer 85: 333-340
4. Mahmoud FA, Rivera NI (2002) The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 4: 250-255
5. Martin F, Santolaria F, Batista N, Milena A, Gonzalez-Reimers E, Brito MJ, Oramas J (1999) Cytokine levels (IL-6 and IFN-gamma) acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11: 80-86
6. McMillan DC, Scott HR, Watson WS, Preston T, Milroy R, McArdle CS (1998) Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. Nutr Cancer 31: 101-105
7. Mountain CF (1991) A new international staging system for lung cancer. Chest 89 (Suppl 4): 225s-233s
8. Numico G, Russi E, Merlano M (2001) Best supportive care in non-small cell lung cancer: is there a role for radiotherapy and chemotherapy? Lung Cancer 32: 213-226
9. O'Gorman P, McMillan DC, McArdle CS (2000) Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 37: 36-40
10. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P, Klastersky J (1997) Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. Eur J Cancer 33: 2326-2332
11. Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R (1996) The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer 73: 1560-1562
12. Scott HR, McMillan DC, Brown DJF, Forrest LM, McArdle CS, Milroy R (2003) A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. Lung Cancer 40: 295-299
13. Scott HR, McMillan DC, Forrest LM, Brown DJF, McArdle CS, Milroy R (2002) The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 87: 264-267
14. Simons JP, Schols AM, Buurman WA, Wouters EF (1999) Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond) 97: 215-223
15. Staal-van den Brekel AJ, Dentener MA, Schols AM, Buurman WA, Wouters EF (1995) Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 13: 2600-2605
16. Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T, Ogura T (1995) Serum levels of interleukin-6 in patients with lung cancer. Br J Cancer 71: 1095-1098